Hepatitis Delta in Focus: Episode 1 of Answering the Questions on Screening, Diagnosis, and Treatment

In this episode, Maria Buti, MD, and Richard H. Davis, PA-C, address key considerations when screening, diagnosing, and treating patients with hepatitis delta virus (HDV), such as:Barriers to screening HDV screening based on patient risk factors Universal screening for all patients with positive hepatitis B surface antigen (HBsAg)Reflex testing Availability of commercial testingMonitoring suggestions in HBsAg positive and HDV antibody positive patients with negative HDV RNALimitations to evaluating advanced fibrosis in patients with HDVData on novel HDV therapies (eg, bulevirtide and lonafarnib)Extending HDV therapy (eg, peginterferon) based on treatment responseStopping rules (eg, HDV RNA negativity, HBsAg loss) for discontinuing HDV therapyFaculty:Maria Buti, MDProfessor of MedicineHospital Universitario Vall d’HebronBarcelona, SpainRichard H. Davis, PA-CSenior PAGastroenterologyUniversity of FloridaUF HealthGainesville, FloridaLink to full program: http://bit.ly/3yp1Lxf Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

There are no comments yet.

Please log in to write the first comment.